Researchers have identified C5aR1 as a novel biomarker for metastasis risk and poor prognosis in patients with cutaneous ...

A common terminal pathway is shared by the above three complement pathways: Under the action of C5 convertase, C5 can be bifurcated into C5a and C5b. C5a, the strongest factor, appears in the ...

“INF904 is a promising addition to our pipeline of candidates controlling the terminal complement C5a / C5aR pathway. As an orally administered compound, we plan to study if INF904 is especially ...

Giamarellos-Bourboulis, from the ATTIKON University, Athens, Greece. The presentation, entitled, Complement split product C5a is elevated in moderate and severe hidradenitis suppurativa ...

InflaRx is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent ...

The cleavage of C5 into fragments C5a and C5b is a critical event during the complement cascade, as C5a is a potent pro-inflammatory anaphylatoxin capable of inducing cell migration, adhesion and ...

InflaRx will participate in a panel - Advances in Dermatology: AD and CSU – being held 10:45-11:20 AM ET, as well as participate in one-on-one investor meetings. Leerink Partners Therapeutics Forum: I ...